Pharmaceuticals company Divi's Laboratories announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Consolidated total income Rs 2,444 crore for Q2FY25 as against a consolidated total income of Rs 1,995 crore for Q2FY24. Profit before tax (PBT) for the Q2FY25 amounted to Rs 722 crore as against a PBT of Rs 469 crore for Q2FY24. Profit after tax (PAT) for the Q2FY25 amounted to Rs 510 crore as against a PAT of Rs 348 crore for Q2FY24. Forex gain of Rs 29 crore as against a gain of Rs 11 crore during Q2FY24. H1FY25 Financial Highlights: Consolidated total income of Rs 4,640 crore as against a consolidated total income of Rs 3,854 crore during H1FY24. PBT for H1FY25 came to Rs 1,326 crore as against Rs 961 crore for H1FY24. PAT for H1FY25 came to Rs 940 crore as against Rs 704 crore for H1FY24. Forex gain of Rs 28 crore against a gain of Rs 14 crore for H1FY24. Result PDF
Conference Call with Divi's Laboratories Ltd. Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Divi's Laboratories announced Q1FY25 results: Financial Highlights: Divi's Laboratories has earned a total income Rs 2,197 crore for Q1FY25 on a consolidated basis as against an income of Rs 1,859 crore for the corresponding quarter of last year. Profit before Tax (PBT) for the current quarter amounted to Rs 604 crore as against a PBT of Rs 492 crore for the corresponding quarter of the last year and a PBT of Rs 713 crore for the fourth quarter of last year. The Company earned a Profit after Tax (PAT) of Rs 430 crore for the current quarter as against a PAT of Rs 356 crore for the corresponding quarter of the last year. PAT for the fourth quarter of last year was Rs 538 crore. Forex loss for the current quarter amounted to Rs 1 crore as against a gain of Rs 3 crore during the corresponding quarter of the last year. Result PDF